Arctic Bioscience - Achieves significant vision improvement in Clinical Glaucoma Study
Börskollen - Aktier, fonder och ekonominyheter
BörskollenFör dig med koll på börsen

Pressmeddelande

Arctic Bioscience - Achieves significant vision improvement in Clinical Glaucoma Study

Arctic Bioscience today announced that a clinical study published in International Ophthalmology demonstrated that daily supplementation with ROMEGA® herring caviar oil resulted in a statistically significant improvement in the visual field measure Mean Deviation (MD) in patients with primary open-angle glaucoma (POAG) and controlled intraocular pressure (IOP). No adverse events were observed, and the treatment was well tolerated.

About the study

The three-month study included 50 patients. The intervention group received one ROMEGA® capsule (500mg) daily. Results showed a clear improvement in MD values in the intervention group (p = 0.01) compared to baseline, while no similar improvement was observed in the control group. Best-corrected visual acuity and retinal nerve fiber layer thickness remained stable, and intraocular pressure was maintained.

Next steps

“These findings suggest that ROMEGA® may be a safe and potentially effective adjunct to protect vision in glaucoma patients, even when IOP is already controlled. We are now planning larger, randomized studies to confirm these promising results”, says Hogne Hallaråker, CSO in Arctic Bioscience.

Link for more info: https://pmc.ncbi.nlm.nih.gov/articles/PMC12279572/

Nyheter om Arctic Bioscience

Läses av andra just nu

Om aktien Arctic Bioscience

Senaste nytt